MR

Mike Ross

Senior Partner at SV Health Investors

San Mateo, California

Overview

Work Experience

SH

SV Health Investors

  • Senior Partner

    2001 - Current

MetaXen

  • CEO

    1993 - 1996

Arris Pharmaceutical

  • CEO

    1990 - 1993

G

Genentech

  • VP Medicinal and Biomolecular Chemistry

    1987 - 1990

  • VP Development

    1981 - 1987

  • Director Protein Chemistry

    1979 - 1981

  • Sr Scientist

    1978 - 1979

Education

Investments

Eyebiotech

Seed

Total Funding: $130M

Therini Bio

Seed

Total Funding: $62M

Xilio Therapeutics

Series A

Total Funding: $330M

Thesan Pharmaceuticals

Series B

Total Funding: $65M

Relevant Websites